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Abstract
The antimalarial drug piperaquine is associated with delayed ventricular depolarization,
causing prolonged QT interval (time taken for ventricular de-polarisation and re-polarisa-
tion). There is a lack of safety data regarding dihydroartemisinin/piperaquine (DHA/PPQ)
for the treatment of uncomplicated malaria, which has limited its use. We created a platform
where electrocardiograms (ECG) were performed in public hospitals for the safety assess-
ment of DHA/PPQ, at baseline before the use of dihydroartemisinin/piperaquine (Eurarte-
sim®), and on day 3 (before and after administration of the final dose) and day 7 post-
administration. Laboratory analyses included haematology and clinical chemistry. The
main objective of the ECG assessment in this study was to evaluate the effect of adminis-
tration of DHA/PPQ on QTc intervals and the association of QTc intervals with changes in
blood biochemistry, full and differential blood count over time after the DHA/PPQ adminis-
tration. A total of 1315 patients gave consent and were enrolled of which 1147 (87%) had
complete information for analyses. Of the enrolled patients 488 (42%), 323 (28%), 213
(19%) and 123 (11%) were from Ghana, Burkina Faso, Tanzania and Mozambique, respec-
tively. Median (lower—upper quartile) age was 8 (5–14) years and a quarter of the patients
were children under five years of age (n = 287). Changes in blood biochemistry, full and dif-
ferential blood count were temporal which remained within clinical thresholds and did not
require any intervention. The mean QTcF values were significantly higher than on day 1
when measured on day 3 before and after administration of the treatment as well as on day
7, four days after completion of treatment (12, 22 and 4 higher, p < 0.001). In all age groups
the values of QT, QTcF and QTcB were highest on day 3 after drug intake. The mean
extreme QTcF prolongation from baseline was lowest on day 3 before drug intake (33 ms,
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SD = 19) and highest on day 3 after the last dose (60 ms, SD = 31). There were 79 (7%)
events of extreme mean QTcF prolongation which were not clinically significant. Nearly a
half of them (n = 37) were grade 3 and mainly among males (33/37). Patients in Burkina
Faso, Mozambique and Tanzania had significantly lower mean QTcF than patients in
Ghana by an average of 3, 4 and 11 ms, respectively. We found no evidence that Eurarte-
sim® administered in therapeutic doses in patients with uncomplicated malaria and no pre-
disposing cardiac conditions in Africa was associated with adverse clinically significant QTc
prolongation.
Introduction
Dihydroartemisinin/piperaquine (DHA/PPQ) is one of the artemisinin based combination thera-
pies (ACTs) effective against uncomplicated malaria. Its use has been limited due reported cardi-
otoxic effects [1]. Currently there is limited data on cardiac effects to warrant wider deployment
of DHA/PPQ. One of the side effects of aminoquinolone group in which piperaquine, a part of
DHA/PPQ combination belongs is the negative effect on heart rhythm through prolongation of
QT intervals [2]. The QT interval is the time from the start of the Q wave to the end of the T
wave and represents the time taken for ventricular de-polarisation and re-polarisation.
The QT prolongation effect can be exacerbated in individuals that are predisposed to a form
of fatal tachy-arrhythmias called torsades de pointes (TdP). In clinical pharmacology prolonged
QT interval is a heart rhythm’s toxicity indicator recorded upon confirmation of Fridericia’s
correction> 450 milliseconds [3,4]. In clinical literature according to the Committee for Pro-
prietaryMedical Products (CPMP) criteria, female adults and male adults are considered to
have a prolonged QT intervals if the calculated Bazzet-correctionexceeds 470 and 450ms,
respectively [5]. It is further suggested by CPMP that while 450ms in adult females and 430ms
in adult males are normal values, values close to 451–470ms in adult females and 431–450ms
in adults males are considered borderline [5]. In 2012 the International Conference on Harmo-
nisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
in collaboration with Food and Drug Administration of United states of America (FDA) issued
revised guidance for Industry (E14) on clinical evaluation of electrocardiographic “Q” and “T”
waves’ (QT/calculated-QTc) interval prolongation for Non-Antiarrhythmic drugs [5]. In this
guidance, details of using Bazett or Fridericia (B/F) formulae for calculated (QTcB/F) is also
presented. It was recommended that outliers be categorized as QTc prolongation adverse
events: Grade 1> 450ms, Grade 2> 480ms, and Grade 3> 500ms, respectively regardless of
gender as opposed to the normal values that would necessarily be investigated in healthy volun-
teers [6]. This paper applied similar cut-off points and defines QTc increase of 30ms and above
from baseline as QTc with extreme prolongation.
In DHA/PPQ the water soluble dihydroartemisinin (DHA) is rapidly absorbed and responsi-
ble for enhanced efficacy of the ACT, suggesting an additive antimalarial effect [7]. Piperaquine
(PPQ) the fat-soluble component of this ACT is solely responsible for the delayed ventricular
depolarization hence QT prolongation. PPQ is one of the 4-aminoquinoline synthetic alkaloids
that kill malaria parasites through intraparasitic detoxification of haem. PPQ is slowly absorbed
after single and multiple dosing with maximum time (Tmax) of about 4–5 hours [8]. The slow
elimination of PPQ in plasma is associated with its long acting properties and this is the main
cause of the QT interval delays particularly in patients prone to QT interval prolongation[1],[9].
In malaria endemic settings there have been no records of fatal QT toxicity incidence following
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treatment with PPQ [10]. This is most probably due to lack of toxicity especially when this anti-
malarial is given as optimal therapeutic dose [11]. However, it could also be due to the limited
knowledge of side effects that go undetected or reported as the result of a lack of ECG equip-
ment which are expensive to implement and require trained staff to use. Most remote health
facilities where a large proportion of uncomplicated malaria is managed do not have ECG
machines. Among the few cases of QTc prolongation following administration of PPQ that have
been reported to date, most are from clinical efficacy follow up trials in which the full ECG eval-
uation is limited and there are few subjects in the low age group of children less than 5 years
[12,13]. In a recently completed meta-analysis of ACT including DHA/PPQ the emphasis was
on efficacy and for DHA/PPQ did not report any safety issues requiring further detailed investi-
gation [14]. In a detailed randomized, double-blind, placebo-controlled clinical trial of DHA/
PPQ in Cambodia a regimen of compressed 2-day treatment courses was associated with the
prolongation of QTcF >500ms among male military servicemenprompting a halt after nearly
twomonths of implementation and suggesting furthermore thorough evaluation with patients
in malaria endemic areas [15]. This trial reported that increased repolarization risk was associ-
ated with repeated and compressed 2 dose regimen, and that this might be mitigated by using a
conventional 3-day regimen, with patients givenmedication on empty stomach and avoiding
repeated dosing or co-administrationwith other QT-prolonging medications [15].
Here we report an investigation of safety of DHA/PPQ with ECG in patients of all age
groups who presented in public health facilities with un-complicated Plasmodium faciparum
malaria in sub-Saharan Africa.
Materials and Methods
Participants’ enrolment
We conducted a post-licensure clinical study to assess safety of DHA/PPQ (Eurartesim1) in
health facilities within the International Network for the Demographic Evaluation of Popula-
tions and Their Health (INDEPTH) [16] over a period of 10 months betweenOctober 2013
and July 2014, S1 Checklist and S1 Protocol. The main objective of the ECG assessment in this
study was to evaluate the relationship of the effect resulted from the administration of DHA/
PPQ on QTc intervals and the association of QTc intervals with changes in blood biochemistry,
full and differential blood count over time after the DHA/PPQ administration.
1315 Patients were enrolled at out-patient Departments (OPDs) fromManhiça Mozam-
bique, Rufiji Tanzania, in three Ghanaian sites; Navrongo, Kintampo and Dodowa as well as in
Nouna and Nanoro both in Burkina Faso. All eligible patients provided written informed con-
sent and assent as appropriate, we also obtained consent from parents or guardians of the
minors (<18 years) that were included in the study.
The inclusion criteria were: 1) willingness to participate in the study, 2) age above 6 months
and 3) provision of consent. Exclusion criteria were: 1) severemalaria, 2) known allergy to arte-
misinin or piperaquine, 3) known pregnancy, 4) lactating women and 5) takingmedicinal
products that are known to prolong the QTc interval (Table 1), 6) having taken a DHA/PPQ
dose in the previous four weeks, 7) family history of sudden unexplained death, or 8) personal
or family history of predisposing cardiac conditions for arrhythmia/QT prolongation (includ-
ing congenital long QT syndrome, arrhythmia, and any knownQTc interval greater than 450
millisecondswith either Bazett or Fridericia correction).
ECG procedure
ECGs were recorded using the 12-lead data collection recorder (Mortara ELI 150) supplied in
collaboration with CardiaBase SAS headquartered in Nancy, France [17]. CardiaBase is a
Modelling of Electrocardiograms for Eurartesim® Safety Evaluation
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leading company in the reading and interpretation of cardiac data with a particular focus on
early phases of clinical trials complying with FDA requirements. ECG ELI files were uploaded
directly to specific computer directory called ELI and sent to CardiaBase. All analytical feed-
back from CardiaBase was sent back to study sites in PDFs. In addition, for each file detailed
QTcF counts were provided to clinicians for compilation and appropriate medical action
required by the participants during DHA/PPQ administration and follow up period.
During ECG, patients were in a relaxed supine position for at least 5–10 minutes before
recording. Patients were further encouraged to breathe normally and remain awake during the
procedure. They were also instructed to remain silent and not touch anything especiallymetal-
lic objects during the recording. All laboratory procedures (blood draws and malaria Rapid
Diagnostic [mRDTs] testing) and blood pressure measurements were performed after the ECG
recording was completed. Younger children remained with their parents in the examination
rooms. Clinicians unplugged the machine from AC power which was battery operated during
recording to avoid contact with metallic objects. The 12 chest leads positioning were standard-
ised across sites for all ECG recording. Electrode cables were joined on to a single use electrode
cell using the International ElectrotechnicalCommission-IECor Association for the Advance-
ment of Medical Instrumentation-AAMI placement systems. Electrodeswere placed on the
chest as follows; (C1 or V1) on the fourth intercostal space at the right sternal border; (C2 or
V2) on the fourth intercostal space at the left sternal border; (C3 or V3) on the midway
betweenV2 and V4; (C4 or V4) on the fifth intercostal space at the left of the mid-clavicular
line; (C5 or V5) along the anterior axillary line at same horizontal level as V4 and (C6 or V6)
along the mid-axillary line on same horizontal level as V4 and V5. The limb connections were;
(R or RA) on the right deltoid fossa, mid-clavicular; (L or LA) on the left deltoid fossa midclavi-
cular; for both upper limbs whereas (N or RL) on the right anterior axillary, mid-clavicular line
and (F or LL) on the left anterior axillary, mid-clavicular line connected lower limbs.
ECG examinations were recorded on Day 1 (before drug administration), twice on Day 3
(i.e. before and 3–4 hours after the last dose administration) as well as on Day 7. The QTcF
(using Fridericia’s cube-root formula) intervals at baseline were considered normal upon con-
firmation of the calculated average QTcF recording of450ms in males and470ms in
females. All ECGs were collected in singly with the exception of ECGs taken on Day 1 and Day
3 after the last dose administration, which were recorded in triplicate. In case of any abnormal-
ity in the QTcF value assessed on baseline before drug intake, DHA/PPQ was withheld until
QTcF returned to normal values, thereafter the DHA/PPQ dose was to be completed under
Table 1. Products that are known to prolong the QTc interval.
Group Type of medicinal product
Antiarrhythmics Amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine,
hydroquinidine, sotalol
Neuroleptics Phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol,
mesoridazine, pimozide, or thioridazine), antidepressive agents
Certain antimicrobial agents Macrolides (e.g. erythromycin, clarithromycin) Fluoroquinolones (e.g.
moxifloxacin, sparfloxacin), Imidazole and triazole antifungal agents
pentamidine and saquinavir
Certain non-sedating
antihistamines
Terfenadine, astemizole, mizolastine.
Antimalarials Mefloquine, halofantrine, lumefantrine, chloroquine, quinine and other
aminoquinoline agents
Others Cisapride, droperidol, domperidone, bepridil, diphemanil, probucol,
levomethadyl, methadone, vinca alkaloids, arsenic trioxide
doi:10.1371/journal.pone.0164851.t001
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frequent QTc monitoring based on investigator clinical judgment. If the QTcF did not return
below 480 ms in male or below 500 ms in female within 6 hours of the DHA/PPQ administra-
tion, another antimalarial therapy was initiated and patient was observed for till the QTcF
returned to normal value during the 28 day follow up.
Drug administration
Eurartesim1 was administered every 24 hours from the first administration over a period of
three days, i.e. on Day 1, then after 24 hours (Day 2) and after 48 hours (Day 3). The dosage
was based on patient’s body weight. Two strengths of Eurartesim1 dosing strengths were used;
20/160mg and 40/320mg of DHA and PQP for children and adults respectively. The drug was
administered with water on empty stomach (no food at least three hours before or three hours
after DHA/PPQ intake). To facilitate drug administration in small children, tablets were
crushed on a spoon and given with water. For those who vomited within 30 min of drug
administration, the dose was re-administered. For vomiting which occurred between 30 and 60
min after administration a half dose was re-administered. Re-dosing was not attempted more
than once. In case of vomiting of rescue repeat dose a rescue treatment was offered immedi-
ately. Research teammembers assessed completion of the full treatment course during home
visits and counted the number of pills remaining to check patient compliance.
Laboratory tests
Plasmodium falciparum microscopy with thick and thin blood smears was performed for
screening of eligible participants. Thick smear was used for parasite counts and the thin smears
for identification of Plasmodium species. Parasite count per 200 white blood cells was used to
calculate parasite density. Any subject found with mixed infections was withdrawn. Venous
phlebotomy was conducted to collect blood for haematology and biochemistry analyses during
scheduled patients visits on Day 1, day 3 (before and after drug administration) as well as on
day 7. Plasma samples were prepared to evaluate: Potassium, Chloride, Urea, ALAT, ASAT
and total Bilirubin.Hematology was performed to evaluate haemoglobin and cell count. Full
and differential blood counts were routinely analyzed using semi-automated and fully-auto-
mated Sysmex haematologymachines (Sysmex Europe GmbH) [18]. For blood biochemistry
we used Cobasmachine (Roche Diagnostics, Roche Group, Basel Switzerland) [19].
Sample size determination
The sample size computation was based on prolonged QTc interval as the major manifestation
of adverse events related to cardio-toxicity following intake of DHA/PPQ. It was therefore
hypothesized that there will be a probability of 0.95 to observe at least one cardiac adverse
event of QT prolongation assuming that the true incidence of these events is 3 per 1000
patients treated with precision of 0.002 and 95% confidence interval. For such probability
therefore nearly 1,000 subjects were to be enrolled for close follow up with ECG
measurements.
Statistical analysis
Summary statistics were calculated to describe the data set and variable distribution. Categori-
cal data were reported using numbers and percentages whereas continuous data was summa-
rized throughmedian and interquartile range (IQR) or mean and standard deviation (SD)
depending on the data distribution.While continuous background demographic information
was presented in median and IQR by age stratification, the mean biochemistry values across
Modelling of Electrocardiograms for Eurartesim® Safety Evaluation
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age groups were presented with SD. Stratification by age groups was also applied in summary
statistics for electrocardiographic readings where each follow up visit was considered as inde-
pendent. QTcF/B was measured on pre-treatment during Day 1, during treatment on day 3
(pre and post treatment) and on day 7 after treatment course.
QTcF/B on day 3 (before and after treatment) was measured in triplicate and the average of
the three measurements was taken to represent the measurement on that time (day 3 before
and after treatment). The Skillings–Mack statistic (Friedman test accounting for missing value)
was used to compare the median of more than two groups.
Events of mean extreme QTc prolongation was based on those patients who had the mean
QTcF above 450ms (male) or 470ms (female) at any point of measurement from baseline fol-
lowing administration of Eurartesim1. The mean prolongation was then calculated by taking
the average difference of QTc in the follow up visits and QTc at baseline. The number of events
was calculated as absolute number of patients who had extreme QTc prolongation above 450
(male) or 470 (female). Grade 1 cardiac event of QTc prolongation was defined as QTc increase
from baseline (above 450 for male and 470 for female) between 0–30ms. Grade 2 was defined
as the increase in QTc from 31–50ms and Grade 3 was the increase in QTc above 50ms from
baseline.
A linear mixed model was fitted to determine the relationship betweenQTcF and risk fac-
tors accounting for between subject variability. A likelihood ratio (LR) test was used to com-
pare the linear mixedmodel with and without random slope and was also used to investigate
the effect of each covariate to be included into the final model. As the QTcF interval was
expected to differ between children and adults, a model with different slopes for each age
groups was fitted and compared with models having similar slope. This was done using both
the likelihood ratio test and Bayesian Information Criteria (BIC). The effect of age (categorical
variable) and day on the QTcF was kept in the model from the beginning of model develop-
ment. Independent variables tested were age, gender, haemoglobin, total bilirubin, ALT, AST,
creatinine, BUN, potassium, chloride, day of blood sampling, bodymass index and country.
The final model was built on the full data set which was then implemented to account for a
complete case data set (the data set with all measurements extracted from all subjects), the
same was used in a stratified analysis by country. A user written program gllammwith 15
quadrature points was used to model both random intercept and random slope. This analysis
utilized STATA version 13 (Stata Corp, Texas, USA) software. P-value of 0.05 and less was con-
sidered statistically significant.
Ethics approval and registration
Written informed consent for adults and assent for minors was obtained from all patients
before study-related activity. Informed consent was also obtained from parents or guardians of
the minors included in the study. The protocol was approved by the institutional and national
ethics committees in Tanzania (Ifakara Health Institute’ institutional review board and the
National ethics committee of the Ministry of Health and Social welfare), Mozambique (Man-
hiça institutional review board: Comité Institucional de Bioética para Saúde do Centro de
Investigação em Saúde da Manhiça and the National ethics committee: Comité Nacional de
Bioética para a Saúde), Ghana (Ghanaian Health ServiceEthical ReviewCommittee) and Bur-
kina Faso (the national ethics committee: Comite d’Ethique pour la Recherche en santé
(CERS)). Dates of approvals differed by country although in all countries relevant approvals
were obtained in 2013 prior to enrolment of the first participant in to the trial. The study was
registered with Clinical trials.gov on May 1, 2013 (NCT02199951) prior to enrolment of the
first subject. Test dugs were outsourced from Sigma Tau in Italy throughMedicine for Malaria
Modelling of Electrocardiograms for Eurartesim® Safety Evaluation
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Venture (MMV) [20]. Eurartesim1 was registered in participating countries before use: Tanza-
nia—Food& DrugAuthority; Ghana—Food and Drugs Board;Mozambique—Ministério da
Saúde Departamento Farmacêutico of the Ministry of Health (MISAU) and in Burkina Faso—
DirectionGenerale de la Pharmacie, du Medicament et des Laboratoire (DGPML) of the Min-
istry of Health.
Results
Clinical and demographic background of study participants
A total of 1315 patients were enrolled in the study. For analysis, we included all subjects who
had at least one ECGmeasurement post treatment (n = 1147; 87%), among whom 1055 sub-
jects had no missing ECG data (the results of the analysis of full data was not different to the
analysis of complete data-results not shown). In total, 168 (13%) subjects missed all post treat-
ment observations for different reasons. One subject (0.1%) withdrew consent, 29 (2%) patients
were excluded for reasons such as failure of phlebotomy and lack of cooperation, 15 (1%)
missed visit, 30 (2%) were Loss To Follow-up (LTFU) and 93 (7%) failed to attend blood sam-
pling and ECGmeasurements on the prescribed follow up visits or specified time (Fig 1). Out
of 1147 patients, 488 (42%) were from Ghana, 323 (28%) were from Burkina Faso, 213 (19%)
were from Tanzania and 123 (11%) were fromMozambique. In total, 552 (48%) were male and
595 (52%) were female. Median (lower—upper quartile) age was 8 (5–14) years. A quarter of
the patients were children under five years of age (287, 25%). Clinical and demographic back-
ground is presented in Table 2. After first dose 31/1147 (3%) vomited within 30 minutes and 7/
1147 (0.6%) vomited between 30 minutes and 1 hour. Only 1/1147 (0.1%) patient vomited on
the second day and none of them vomited on the third day.
Effect of Eurartesim® on Biochemistry and Haematology
Young children were more anaemic as compared to older children and adults who were least
anaemic (Table 2). The median biochemistry values across age groups during Eurartesim1
treatment periodwere recorded low as compared to baseline values on Day 1 (Table 3).
Although not completely returned to normal, these values tended to reverse to baseline values
by day 7 after completion of the full treatment course. The exception to this was potassium
value at baseline was the only value that was recorded higher on day 3 or day 7 than on day 1
(The Skillings–Mack statistic test p-value< 0.05). Creatinine in children was also lower than
the acceptable ranges whereas in general all these changes remained within clinical thresholds
that did not require further interventions.
Effect of Eurartesim® on QTcF
Children less than 5 years of age had a lower mean QTcF (392.2 ± 1.0) as compared with chil-
dren of older ages; 5–12 years (404.42 ± 0.7), 12–18 years (412.1 ± 1.4) and adults (411.8 ± 1.1),
p-value<0.001. At baseline the mean QTcF was the same in male and female subgroups (Fig
2). In all age groups the mean QTcF was increasing during the Eurartesim1 treatment period
and declined in the later days at the end of treatment course (Figs 3 and 4).
In all age groups the values of QT, QTcF and QTcB were significantly higher on day 3 after
drug intake than any other day. R-R was recorded high on day 3 in all age groups after drug
intake which was statistically significant different from day 1 (Skillings–Mack statistic test p-
value< 0.001). Heart rate following drug intake on day 1 and subsequent days was clinically
and statistically differently low as compared to the value on baseline confirmingQT prolonga-
tion with dosing, p-value< 0.001 (Table 4).
Modelling of Electrocardiograms for Eurartesim® Safety Evaluation
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Table 2. Clinical and demographic background of study participants. Data presented are Median and Interquartile Range (IQR) for each
measurement.
Attributes Age group*
Parameter 6 months—5 years 5—< 12 years 12—< 18 years 18+ years Total
287 (25.0%) 507 (44.2%) 143 (12.5%) 210 (18.3%) 1147
Age (years) 3.5 (1.6) 7.6 (3.1) 13.9 (2.0) 30.1 (24.8) 8.1** (8.7)
Weight (kg) 12.9 (4) 20.9 (7.3) 40 (15.0) 59.0 (14.0) 21.4 (25.0)
Height (cm) 93 (12.0) 121 (19) 151 (18.0) 162.0 (11.5) 124.0 (44.0)
Haemoglobin (g/dl) 9.4 (2.1) 10.6 (1.7) 11.6 (1.7) 12.2 (2.1) 10.7 (2.3)
*number of participants and percentage of total cohort by age group
** Median (IQR) for cohort.
doi:10.1371/journal.pone.0164851.t002
Fig 1. Patients’ flow.
doi:10.1371/journal.pone.0164851.g001
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Effect of Eurartesim® on QTcF—statistical analysis
The final model included both random intercept and random slope (including random slope in
a model gave the LR test of 5.66, p-value 0.03). The mean QTcF peaked on day 3 after the last
dose of Eurartesim1 but decreased thereafter to the value close to baseline on day 7 (Fig 3). The
mean QTcF on day 3 before treatment, day 3 after treatment and on day 7 were 12, 22 and 4
higher than that on Day 1 (p-value< 0.001) Table 5. The mean QTcF in children who are 5—
< 12 years was higher by 13 ms (95% confidence interval 10.1, 15.0) than the mean QTcF in
children whose age were 6 months to 5 years. Similarly, the mean QTcF in older children was
about 20 higher than the mean QTcF in counterpart children who are 6 months to 5 years
Table 3. Background and laboratory parameters.
Parameter Day 1*
(n = 1143)
Day 3*
(n = 1127)
Day 7*
(n = 1121)
Normal values p-valuea
6 months—< 5 years
Bilirubin total (μmoll−1) 12.1 (12.4) 6.3 (5.2) 7.3 (5.6) <25.7 < 0.001
ALT (UL−1) 28.8 (19.9) 23.7 (14.7) 25.3 (14.7) Feb-60 < 0.001
AST (UL−1) 29.7 (18.4) 26.0 (16.4) 27 (15.9) 15–55 < 0.001
Creatinine (μmolL−1) 31.9 (16.7) 29.9 (15.9) 29.0 (13.3) 20–62 < 0.001
BUN (mmolL−1) 3.2 (2.3) 2.6 (1.9) 2.5 (1.7) 1.7–8.3 < 0.001
Potassium (mmolL−1) 4.1 (0.9) 4.1 (1.1) 4.4 (0.8) 3.5–5.6 < 0.001
Chloride (mmolL−1) 102.5 (10.9) 104.0 (9.9) 104.5 (8.2) 96–105 < 0.001
5—< 12 years
Bilirubin total (μmoll−1) 12.5 (14.2) 5.7 (5.4) 6.2 (5.0) <25.7 < 0.001
ALT (UL−1) 24.3 (13.5) 22.0 (13.4) 23.0 (13.6) Feb-60 < 0.001
AST (UL−1) 26.5 (160) 24.8 (13.7) 25.0 (13.1) 15–55 < 0.001
Creatinine (μmolL−1) 41.0 (21.1) 40.1 (21.7) 39.6 (19.5) 55–97 < 0.001
BUN (mmolL−1) 3.9 (3.5) 3.3 (3.1) 3.3 (2.9) 1.7–8.3 < 0.001
Potassium (mmolL−1) 4.1 (0.7) 4.1 (0.7) 4.3 (0.6) 3.5–5.6 < 0.001
Chloride (mmolL−1) 103 (8.8) 103.7 (8.4) 103 (7.8) 96–105 0.0073
12—< 18 years
Bilirubin total (μmoll−1) 15.4 (16.4) 7.3 (5.9) 7.6 (6.3) <25.7 < 0.001
ALT (UL−1) 22.0 (15.2) 22.2(12.6) 23.3 (12.7) Feb-60 0.7524
AST (UL−1) 23.7 (13.4) 23.5 (14.1) 23.5 (12.6) 15–55 0.6303
Creatinine (μmolL−1) 55.5 (24.7) 58.7 (28.1) 53.0 (29.1) 55–97 0.0013
BUN (mmolL−1) 4.2 (5.6) 3.9 (4.0) 3.1 (3.0) 1.7–8.3 < 0.001
Potassium (mmolL−1) 4.1 (0.7) 4.1 (0.7) 4.3 (0.6) 3.5–5.6 < 0.001
Chloride (mmolL−1) 101 (9.2) 102.4 (9.5) 102.5 (7.3) 96–105 0.002
18 + years
Bilirubin total (μmoll−1) 14.0 (15.3) 8.0 (7.4) 9.1 (7.0) <25.7 < 0.001
ALT (UL−1) 22.9 (17.8) 22.5 (17.2) 23.3 (18.0) Feb-60 0.1931
AST (UL−1) 22.8 (15.1) 24.0 (15.2) 23.7 (13.5) 15–55 0.6815
Creatinine (μmolL−1) 71.3 (33.7) 73.2 (33.6) 72.6 (30.2) 55–97 0.1315
BUN (mmolL−1) 3.8 (3.9) 4.0 (3.4) 3.8 (3.2) 1.7–8.3 0.3926
Potassium (mmolL−1) 4.1 (0.8) 4.1 (0.7) 4.3 (0.8) 3.5–5.6 < 0.001
Chloride (mmolL−1) 101.0 (12.5) 103 (9.4) 103 (9.7) 96–105 0.1057
* Values in Median (interquartile range),
a The Skillings–Mack statistic p-value comparing median value for each parameter over days.
doi:10.1371/journal.pone.0164851.t003
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(Table 5). Adults (aged 18 and above) presented with the mean QTcF of 0.8 (95% confidence
interval: -4.4, 2.9) lower than in children age between 12 to less than 18 years.
Country-wise the results of Mozambique site, children who were between 5 and 12 years
had the mean QTcF of 22 ms more than children aged 6 months to 5 years. Similarly in Tanza-
nia adults (18+ years) had the mean QTcF of 7 ms more than the youngest children at the end
of their treatment course although this was on borderline significant. Patients in Burkina Faso,
Mozambique and Tanzania had significant lower mean QTcF than patients in Ghana by an
average of 3, 4 and 11 ms respectively (Table 5).
Children aged between 12 and 18 years had a mean QTcF of 7.5 (95% confidence interval:
4.4, 10.6) ms which was greater than children aged between 5 and 12 years. The mean QTcF in
patients 18 years and above was 6.7 (95% confidence interval: 3.7, 9.6) ms higher than children
who are 5 to less than 12 years (results not in tables).
On day 7 the mean QTc in male adults was slightly higher than that at baseline on day 1 by
nearly 2 (95% confidence interval. -1.1, 4.5) ms [after having peaked with nearly 17 (13.6, 19.6)
ms on day 3] as compared to counterpart adult females. In children, boys aged between 6
months and 5 years had significantly 5 (95% confidence interval 1.6, 8.6) higher mean QTcF
compared to girls of the same age (Table 6).
Mean extreme QTcF prolongation from baseline was highest (60 ms) on day 3 after the last
dose and lowest on the same day (33 ms) before last dose. On day 7 after treatment there was a
Fig 2. Mean QTcF over time by sex.
doi:10.1371/journal.pone.0164851.g002
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downturn in the mean QTcF as compared to baseline which was recorded as 47 ms. In total we
observed79 (7%) extrememean QTcF prolongation events from baseline which were also not
clinically significant. The distribution of the extreme QTcF prolongations was 15 (19%), 58
(73%) and 6 (8%) recorded on day 3 before drug intake, day 3 post drug intake and on day 7
after treatment respectively. Almost a half of all extreme QTcF prolongation events that
occurredwere grade 3, (37/79) whereas male accounted the majority (33/37) and children aged
5-<12 years were more than a half of all grade 3 extreme prolongation cases (n = 19). Male
patients had majority of QTcF prolongation events than female throughout the treatment
period (Table 7).
Discussion
Whereas use of ECG for cardiotoxicity evaluation of other ACTs has been well detailed in liter-
ature, this study gives additional evidence of safety of DHA/PPQ (Eurartesim1) evaluated by
the incorporation of ECG and laboratory measurements of changes in patients treated with
Eurartesim1. DHA/PPQ is one of the antimalarials that has shown a good efficacy against P.
falciparum infection [2,21,22,23,24,25]. Acute P.falciparummalaria fever, especially the severe
form is also associated with tachyarrhythmia a manifestation form of shortening of QT interval
[26] of which the recovery is characterized by QT prolongation [27]. In this study the mean
QTcF at baseline was within normal range, almost in all age categories of patients that
Fig 3. Mean QTcF over time by age groups.
doi:10.1371/journal.pone.0164851.g003
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participated who received Eurartesim1. There were prolongations in the mean QTcF during
the course of treatment with Eurartesim1 that was provided on Day 1 through Day 3. These
changes were recorded in 79 cases of extreme QTcF prolongation that reverted to initial base-
line QTc values in most patients on Day 7. In this study, QTc maximum prolongation was
observedon Day 3 corresponding to what would be considered onset of peak plasma concen-
tration of piperaquine following the last dose administration [11]. Peaks of QTcF were
recorded alongside minimum laboratory biochemistry values (except for potassiumwhich was
in reverse) that were also measured low during treatment as compared to the maximum values
that were recorded at baseline with some restorations on day 7. There was sound difference in
the mean values of QTcF prolongation between baseline and during treatment among 79 sub-
jects. Although the mean QTcF was such extreme these changes were not associated with sig-
nificant clinical adverse condition. The occurrences of extreme QTc prolongation we have
observedwere mostly in children who are 5 to< 12 years devoid of any sound clinical cardio-
genic adverse conditionmight indicate the possibility of a wider therapeutic threshold in this
group of children relative to younger children or adults was warranted. Another line of deduc-
tion would be that probably this prolongation in the mean QTcF intervals and the recovery
thereof reflects the recovery from acute malaria episode [27]. Our study was not powered to
look at this detailed difference.Moreover, in this study we did not see any complete restoration
of QTcF on day 7 the phenomena that would have reflected the residual piperaquine in the
blood of which required an extended time of observation to ascertain the full restoration.
Despite the modest prolongation that was observed in this study as compared to baseline
Fig 4. Mean QTcF by age groups over days.
doi:10.1371/journal.pone.0164851.g004
Modelling of Electrocardiograms for Eurartesim® Safety Evaluation
PLOS ONE | DOI:10.1371/journal.pone.0164851 October 20, 2016 12 / 19
values, this prolongation is of little clinical relevance as it did not exacerbate any clinical sound
cardiac manifestation of arrhythmia [5]. In the literature extreme QTc prolongation following
drug administration are often associated with fatal form of arrhythmia known as torsades de
pointes. In our study QTcF prolongation that we observeddid not worsen to torsades de pointes
most probably due to the therapeutic dose that we used being within safety margin of therapeu-
tic thresholds. Reversible ECG changes from baseline on day 1 as demonstrated through the
recession of mean QTc interval values recorded on day 7 suggests the safety of the optimal
therapeutic dose of Eurartesim1 among African patients with uncomplicated malaria is war-
ranted. One would suggest that perhaps we did not see untoward extrememaximumQTc pro-
longation in the study population because all patient with the history of cardiac problems were
excluded at baseline. This position has some bearing and cannot go without comment. Our
approach was to exercise utmost safety precautions and this might have enabled us to avoid
any unnecessary torsadogenic events that might resulted, had we included-pro-arrhythmic
patients. These findings also reflect the classic overall presentation of plasma concentration
Table 4. Electrocardiogram readings.
Parameter Day 1*
(n = 1137)
Day 3 before
(n = 1132)
Day 3 after
(n = 1132)
Day 7
(n = 1069)
p-valuea
6 months—5 years
R-R (ms) 480 (91) 538 (101) 535 (95) 528 (104) < 0.001
Heart rate (bpm) 126 (23) 112 (21) 113 (21) 113 (21) < 0.001
QRS(ms) 72 (6) 72 (7) 73 (7) 72 (6) < 0.001
QT (ms) 301 (39) 322 (32) 325 (38) 315 (33) < 0.001
QTcF (ms) 385 (31) 397 (25)6¼ 400 (27)6¼ 387 (26) < 0.001
QTcB (ms) 434 (25) 440 (23)6¼ 445 (25)6¼ 430 (26) < 0.001
5—< 12 years
R-R (ms) 571 (143) 660 (148) 668 (135) 646 (131) < 0.001
Heart rate (bpm) 105 (26) 91 (20) 90 (19) 92 (19) < 0.001
QRS(ms) 77 (8) 78 (8) 78 (8) 77 (7) < 0.001
QT (ms) 333 (46) 357 (39)6¼ 365 (46)6¼ 346 (35) < 0.001
QTcF (ms) 394 (29) 407 (26)6¼ 417 (29)6¼ 398 (23) < 0.001
QTcB (ms) 431 (26) 437 (28)6¼ 445 (29)6¼ 429 (24) < 0.001
12—< 18 years
R-R (ms) 648 (175) 758 (182) 764 (158) 743 (155) < 0.001
Heart rate (bpm) 93 (25) 79 (19) 78 (16) 80 (17) < 0.001
QRS(ms) 84 (11) 85 (10) 85 (10) 83 (11) < 0.001
QT (ms) 348 (48) 377 (38)6¼ 393 (43)6¼ 369 (33) < 0.001
QTcF (ms) 399 (26) 412 (23)6¼ 430 (28)6¼ 405 (25) < 0.001
QTcB (ms) 428 (20) 433 (29)6¼ 449 (31)6¼ 426 (30) < 0.001
18+ years
R-R (ms) 729 (213) 801 (219) 836 (176) 811 (202) < 0.001
Heart rate (bpm) 82 (22) 75 (19) 71 (16) 73 (17) < 0.001
QRS(ms) 87 (11) 88 (12) 89 (10) 88 (10) 0.0056
QT (ms) 365 (47) 390 (44)6¼ 400 (43)6¼ 380 (38) < 0.001
QTcF (ms) 403 (27) 412 (35)6¼ 422 (36)6¼ 409 (28) < 0.001
QTcB (ms) 426 (26) 427 (29)6¼ 435 (33)6¼ 425 (30) < 0.001
* Values in Median (interquartile range),
a The Skillings–Mack statistic p-value comparing median value for each parameter over days.
doi:10.1371/journal.pone.0164851.t004
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levels that are expected to decline around day 7 correspondingQTc recovery [11]. In the by-
country comparison however, one of the possible explanations for the modest QTc prolonga-
tion that was noted in some patients from Ghana as compared to the rest might also be due to
other factors that were not investigated in this study such as genetic or dietary factors.
Table 5. Country-wise parameter estimates from linear mixed model.
Parameter ALL Ghana Burkina Faso Mozambique Tanzania
Estimate (SE) 95% CI Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE)
Constant 386.4 (1.6)** 383.3, 389.6 388.2 (2.3)** 388.8 (2.8)** 370.4 (13.2)** 377.0 (3.6)**
6 months—< 5 years (reference)
5—< 12 years 12.6 (1.3)** 10.1, 15.0 13.8 (1.8)** 10.9 (2.1)** 22.2 (13.1) 11.4 (3.3)*
12—< 18 years 20.0 (1.8)** 16.5, 23.5 23.4 (2.6)** 19.7 (4.2)** 27.9 (13.7)* 18.6 (4.3)**
18+ years 19.2 (1.8)** 15.8, 22.7 23.3 (2.8)** 25.5 (4.1)** 32.2 (14.3)* 7.3 (3.7)‡
Ghana (reference)
Burkina Faso -2.5 (1.2)* -5.0, -0.1 - - - -
Mozambique -3.8 (1.7)* -7.1, -0.5 - - - -
Tanzania -10.8 (1.5)** -13.7, -7.9 - - - -
Day 1 (reference)
Day 3 pre-treatment 12.0 (0.7)** 10.6, 13.4 14.2 (0.9)** 4.9 (1.1)** 24.7 (2.6)** 11.0 (2.0)**
Day 3 after treatment 22.1 (0.7)** 20.7, 23.5 27.5 (0.9)** 11.9 (1.1)** 44.2 (2.6)** 12.5 (2.0)**
Day 7 3.7 (0.7)** 2.3, 5.1 3.5 (0.9)** 1.5 (1.1) 11.2 (2.7)** 3.4 (2.1)
Bilirubin total -0.2 (0.0)** -0.2, -0.1 -0.2 (0.0)** -0.2 (0.1)* -0.1 (0.1) -0.0 (0.1)
Creatinine 0.0 (0.0) 0, 0.1 -0.1 (0.0) 0.1 (0.1) -0.2 (0.2) 0.1 (0.0)**
** P-value < 0.001,
* p-value < 0.05,
‡ borderline significant.
doi:10.1371/journal.pone.0164851.t005
Table 6. Age category based parameter estimates from linear mixed model.
Parameter 6 months—< 5 years 5—< 12 years 12—< 18 years 18+ years
Estimate (SE) 95% CI Estimate (SE) 95% CI Estimate (SE) 95% CI Estimate (SE) 95% CI
Constant 380.4 (3.1)** 374.4; 386.4 396.2 (2.6)** 391.2; 401.2 406.3 (4)** 398.5; 414.1 409.8 (4.2)** 401.6; 417.9
Ghana (reference)
Burkina Faso -1.4 (2) -5.4; 2.6 -4.2 (1.9)* -7.9; -0.5 -3.9 (4) -11.8; 3.9 4.8 (3.2) -1.5; 11
Mozambique -8.7 (11.1) -30.4; 13.1 -2.7 (2.3) -7.1; 1.8 -7.2 (3.4)* -13.9; -0.5 -3.1 (4.1) -11.1; 4.9
Tanzania -9.9 (3.1)* -16; -3.9 -8.6 (2.3)** -13.2; -4.1 -8.8 (3.4)* -15.4; -2.1 -15.8 (3.4)** -22.4; -9.2
Day 1 (reference)
Day 3 pre-treatment 11.1 (1.4)** 8.3; 13.9 13.9 (1.1)** 11.8; 16 14.1 (1.9)** 10.4; 17.9 7.3 (1.5)** 4.4; 10.3
Day 3 after treatment 18.6 (1.4)** 15.8; 21.4 24.5 (1.1)** 22.4; 26.6 28.6 (1.9)** 24.9; 32.4 16.6 (1.5)** 13.6; 19.6
Day 7 3.2 (1.5)* 0.3; 6 4.1 (1.1)** 1.9; 6.3 5.8 (2)* 2; 9.7 1.9 (1.5) -1.1; 4.9
Female (Reference)
Male 5.1 (1.8)* 1.6; 8.6 1.7 (1.4) -1.2; 4.5 -0.9 (2.5) -5.8; 4 -12.6 (2.8)** -18.1; -7
Bilirubin total -0.2 (0.1)* -0.3; 0 -0.2 (0)** -0.3; -0.1 -0.2 (0.1)* -0.3; 0 0 (0.1) -0.2; 0.2
Creatinine 0.2 (0.1)* 0; 0.3 0.1 (0) 0; 0.1 0 (0) -0.1; 0.1 0 (0) 0; 0.1
** P-value < 0.001,
* p-value < 0.05.
doi:10.1371/journal.pone.0164851.t006
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In classic QT interval evaluation studies, positive controls are often used to test the study’s
ability to detect the endpoint of interest, i.e., the QTc interval above the maximum normal
thresholds of480ms. In the current study our design was destined to detect rare SAE due to
cardiotoxicity from a therapeutic dose of Eurartesim1 in a large population exposure. The use
of positive control in a post licensure surveillance study was therefore not envisaged. The
design employed by this study aimed to measure the QTc effect of Eurartesim1 currently used
after subsequent dosing through a well-established regimen of days 1–3 with subsequent ECG
changes as compared to the ones recorded at baseline. It is for this reason that modeling of
ECG outcome was crucial to quantify the finding of no QT effect if the size relative to the con-
trol is evident had the control been considered. It is thus imperative to note here that any value
of changes in QTc that have beenmodelled in this study represented a crucial addition piece of
evidence on changes in QTc during treatment of uncomplicated malaria with Eurartesim1.
Blood chemistry and haematology exhibited temporal changes that remained within clinical
thresholds not requiring any interventions. This phenomena also confirms that limited thera-
peutic Eurartesim1 toxicity was equally tolerated across all parameters that we carried out the
measurements. It can therefore modestly be asserted that Eurartesim1 in current therapeutic
dose has limited clinical toxicity consistent with QTc intervals prolongation when the drug is
used in none-pro-arrhythmic uncomplicated malaria patients.
Table 7. QTcF extreme prolongation from baseline to Day 3 and Day 7.
Attribute Mean (SD) increase from baseline Events n (%) Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%)
Day 3 before dose
Total 33.4 (18.9) 15 (1.3) 7 (0.6) 5 (0.4) 3 (0.3)
Male 31.4 (18.9) 13 (2.4) 7 (1.3) 4 (0.7) 2 (0.4)
Female 46.2 (17.7) 2 (0.3) 0 1 (0.2) 1 (0.2)
6 months—< 5 years - 0 0 0 0
5—< 12 years 34.8 (18.0) 6 (1.2) 2 (0.4) 3 (0.6) 1 (0.2)
12—< 18 years 41.3 (19.2) 6 (4.2) 2 (1.4) 2 (1.4) 2 (1.4)
18 + years 14.8 (7.5) 3 (1.4) 3 (1.4) 0 0
Day 3 after dose
Total 59.9 (31.1) 58 (5.1) 7 (0.6) 14 (1.2) 37 (3.2)
Male 61.6 (32.3) 50 (9.1) 5 (0.9) 12 (2.2) 33 (6.0)
Female 49.3 (21.4) 8 (1.3) 2 (0.3) 2 (0.3) 4 (0.7)
6 months—< 5 years 66.0 (13.8) 6 (2.1) 0 1 (0.4) 5 (1.7)
5—< 12 years 64.0 (35.7) 30 (5.9) 3 (0.6) 8 (1.6) 19 (3.8)
12—< 18 years 56.1 (28.2) 15 (10.5) 1 (0.7) 4 (2.8) 10 (7.0)
18 + years 45.6 (24.9) 7 (3.3) 3 (1.4) 1 (0.5) 3 (1.4)
Day 7 after treatments
Total 46.9 (27.8) 6 (0.5) 1 (0.1) 3 (0.3) 2 (0.2)
Male 40.0 (25.4) 5 (0.9) 1 (0.2) 3 (0.5) 1 (0.2)
Female 79.7 (0)* 1 (0.5) 0 0 1 (0.2)
6 months—< 5 years 43.3 (0)* 1 (0.4) 0 1 (0.4) 0
5—< 12 years 51.6 (20.9) 3 (0.5) 0 2 (0.4) 1 (0.2)
12—< 18 years - 0 0 0 0
18 + years 41.8 (27.8) 2 (1.0) 1 (0.5) 0 1 (0.5)
* Only one subject had prolonged QTcF (therefore SD not calculated).
doi:10.1371/journal.pone.0164851.t007
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Limitations
One of the limitations of our results is the lack of direct extrapolation to people who are prone
to cardiac problems due to our set exclusion criteria.We restricted enrolment of all subjects
that had history of predisposing cardiac conditions for arrhythmia and those contraindicated
to products that are known to prolong the QTc interval [9]. Our choice to exclude subjects of
this type is in line with most post-marketing safety evaluation settings that limit uncontrolled
exposure to subjects with visible risk under the evaluation.
The second limitation is the fact that QT prolongation reported by our study was a modest
increase that could have been due to recovery from acute malaria. Again this setback would
have been dealt by comparison with other antimalarial treatment with established lack of cardi-
otoxicity. Our study was designed to assess safety of antimalarial in a post licensure environ-
ment and the findings we have reported correspond to this setting. Lastly is the limitation that
the modest difference in QTc changes we have observed among cases, cannot be compared with
subjects that would have been included but in this case excluded at baseline for reasons of pre-
disposing cardiac conditions for arrhythmia or who took other antimalarial that cause QT pro-
longation. This was based on history, as we did not investigate at baseline the QTc status in all
individuals that were screened for inclusion. Screening of this type is in particular not feasible to
be implemented in the routine health care setting.We also confirm that our findingsmay not be
extrapolated to patients who are predisposing to cardiac conditions for arrhythmia or those
whomight have taken antimalarial that cause QT prolongation because they were excluded.
This paper reports on a study that recorded few other adverse events that were not directly
related to ECG prolongation as was reported previously by the co-author of this paper elsewhere
[28]. It was recorded that a modest non-clinically significant increase in QT interval which also
normalized after treatment without involving any intervention was seen. These findings corrob-
orates the widely documented invitro animal studies in which the possible lack of huge pro-
longation or torsadogenic cardiac risk in human when DHA/PPQ is used could be related with
the current dose as being optimal therapeutic dose [1]. The findings fill the existing gap in evi-
dence to warrant a wider use of few available highly effectiveACT in malaria endemic settings.
Conclusion
This study has demonstrated the methodologyof field based ECG recording being deployed in
remote health facilities for drug safety evaluation. The study has also demonstrated that despite
long half-life of piperaquine no clinically significant cardiovascular or metabolic effects were
observed among African patients with uncomplicated P.falciparummalaria. Therefore we
found no evidence that dihydroartemisinin/piperaquine administered in therapeutic doses in
patients with uncomplicated malaria and no predisposing cardiac conditions in Africa was
associated with adversely clinical significant QTc prolongation.
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